Sanofi’s Sarclisa combination shows positive results in multiple myeloma patients
Sarclisa is a monoclonal antibody which targets a specific epitope on the CD38 receptor on multiple myeloma cells
Read More
Tag: Sarclisa
EC approves new Sarclisa indication
Sarclisa has been approved in combination with a standard of care regimen for relapsed multiple myeloma
Read More
FDA green light for Sarclisa combo in multiple myeloma
CD38 inhibitor approved in combination with carfilzomib and dexamethasone
Read More
NICE backs use of new treatment for multiple myeloma
Sanofi’s Sarclisa gets the final green light for use by the NHS with funding from the CDF
Read More
Sanofi’s Sarclisa bags NICE recommendation
Treatment is approved for relapsed/refractory multiple myeloma
Read More
NICE rejects Sanofi’s Sarclisa in preliminary guidelines
It is not certain how much more clinical benefit Sarclisa has over existing therapies, the Institute said
Read More
Sanofi’s Sarclisa cleared in Europe for multiple myeloma
Multiple myeloma is the second most common blood cancer, with around 40,000 new cases per year in Europe
Read More
Sanofi’s Sarclisa cuts death risk in mutiple myeloma
The Phase III IKEMA trial hit its primary endpoint
Read More
CHMP gives Sanofi positive opinion for Sarclisa
Despite available treatments, multiple myeloma remains an incurable malignancy, and is associated with significant patient burden.
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
